Clareo Health | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of Polymyalgia Rheumatica (PMR) and fulfillment of the 2012 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) provisional classification criteria for PMR.
Must have had at least 2 episodes of unequivocal PMR flare.
Must be on a stable dose of prednisone.
Must be willing to follow the protocol-defined glucocorticoid tapering regimen.
You may not be if
Have been treated with a prior TNF antagonist.
Current use of immunomodulators other than prednisone and hydroxychloroquine.
